BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 9, 2024
See today's BioWorld
Home
» ROR1s, roar twice: ADC pro Siegall takes on tricky target at Immunome
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ROR1s, roar twice: ADC pro Siegall takes on tricky target at Immunome
Feb. 7, 2024
By
Randy Osborne
No Comments
Immunome Inc. gained renewed attention for its pipeline by way of the Feb. 6 deal to buy from Ayala Pharmaceuticals Inc. the phase III-stage small-molecule gamma secretase inhibitor AL-102 (plus related drug candidate AL-101).
BioWorld
Deals and M&A
Cancer